Spotlight on Fluvoxamine in Anxiety Disorders in Children and Adolescents

@article{Cheer2002SpotlightOF,
  title={Spotlight on Fluvoxamine in Anxiety Disorders in Children and Adolescents},
  author={S. Cheer and D. Figgitt},
  journal={CNS Drugs},
  year={2002},
  volume={16},
  pages={139-144}
}
  • S. Cheer, D. Figgitt
  • Published 2002
  • Medicine
  • CNS Drugs
  • AbstractFluvoxamine is a selective serotonin reuptake inhibitor (SSRI) which may be used for the management of anxiety disorders in children and adolescents. Absorption of fluvoxamine was similar in adolescents to that in adults, which suggests that the maximum dosage of the drug for patients aged between 12 and 17 years can be as high as 300 mg/day. However, steady-state plasma fluvoxamine concentrations were 2 to 3 times higher in children (aged between 6 and 11 years) than in adolescents… CONTINUE READING
    15 Citations
    Treatment of depression with selective serotonin inhibitors: the role of fluvoxamine
    • 2
    Pharmacologic management of anxiety disorders in children and adolescents
    • 33
    Selective serotonin reuptake inhibitor-induced sexual dysfunction in adolescents: a review.
    • A. Scharko
    • Medicine, Psychology
    • Journal of the American Academy of Child and Adolescent Psychiatry
    • 2004
    • 19
    Child and adolescent psychopharmacology update.
    • 25
    [Comorbidity in attention deficit hyperactivity disorder].
    • 1
    Disordered Gambling in Adolescents
    • 15

    References

    SHOWING 1-10 OF 43 REFERENCES
    Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
    • 101
    Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents.
    • 13
    • PDF
    Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.
    • M. Riddle, E. Reeve, +8 authors J. Walkup
    • Psychology, Medicine
    • Journal of the American Academy of Child and Adolescent Psychiatry
    • 2001
    • 305
    Preclinical evidence on the psychotropic profile of fluvoxamine.
    • 37